nps-568 has been researched along with Hyperparathyroidism in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 16 (69.57) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, NX; Chen, X; Duan, D; Gattone, VH; Henley, C; Martin, D; Moe, SM; Seifert, MF; Sinders, RM | 1 |
| Chen, NX; Duan, D; Gattone, VH; Henley, C; Martin, D; Moe, SM; Seifert, MF; Sinders, RM | 1 |
| Christopoulos, A; Gnacadja, G; Lu, JY; Reagan, JD; Yang, Y | 1 |
| Christopoulos, A; Conigrave, AD; Davey, AE; Leach, K; Sexton, PM; Valant, C | 1 |
| Antoniucci, DM; Shoback, D | 1 |
| Cohen, A; Silverberg, SJ | 1 |
| Hoppe, A; Rybczyńska, A | 1 |
| Fujiyama, K | 2 |
| Nemeth, EF | 1 |
| Krebs, LJ | 1 |
| Boblewski, K; Drewnowska, K; Foks, H; Hoppe, A; Lehmann, A; Orlewska, C; Rybczyńska, A | 1 |
| Lindberg, JS | 1 |
| Chudek, J; Piecha, G; Wiecek, A | 1 |
| de Vernejoul, MC; Legoupil, N; Ureña, P | 1 |
| Nagano, N | 1 |
| Aguilera-Tejero, E; Almaden, Y; Cañadillas, S; Canalejo, A; Lopez, I; Martin, D; Rodriguez, M; Rodriguez, ME; Siendones, E | 1 |
| Bilezikian, JP; Bone, HG; Dziem, G; Kaatz, S; Locker, FG; Marriott, TB; Sanguinetti, EL; Silverberg, SJ; Thys-Jacobs, S | 1 |
| Andress, DL; Antonsen, JE; Sherrard, DJ | 1 |
| Fox, J; Furuya, Y; Ishii, H; Nagano, N; Nemeth, EF; Wada, M | 1 |
| Sugimoto, T | 1 |
| Nagano, N; Nemeth, EF; Wada, M | 1 |
| Coburn, JW; Elangovan, L; Frazaõ, JM; Goodman, WG | 1 |
14 review(s) available for nps-568 and Hyperparathyroidism
| Article | Year |
|---|---|
Calcimimetics in the treatment of primary hyperparathyroidism.
Topics: Aniline Compounds; Animals; Calcium; Clinical Trials as Topic; Humans; Hyperparathyroidism; Molecular Mimicry; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 2002 |
Calcimimetics: therapeutic potential in hyperparathyroidism.
Topics: Aniline Compounds; Calcium; Cinacalcet; Homeostasis; Humans; Hyperparathyroidism; Molecular Mimicry; Naphthalenes; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 2002 |
[Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion].
Topics: Aniline Compounds; Calcium; Calcium Channel Blockers; Cinacalcet; Humans; Hyperparathyroidism; Naphthalenes; Phenethylamines; Propylamines | 2003 |
[Bone status in primary hyperparathyroidism].
Topics: Aniline Compounds; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Estrogen Replacement Therapy; Fractures, Bone; Humans; Hyperparathyroidism; Parathyroidectomy; Phenethylamines; Propylamines; Risk | 2004 |
Calcimimetic and calcilytic drugs: just for parathyroid cells?
Topics: Aniline Compounds; Animals; Calcium; Calcium Channels; Cinacalcet; Fendiline; Humans; Hyperparathyroidism; Naphthalenes; Osteoporosis; Parathyroid Glands; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Stereoisomerism | 2004 |
Calcimimetics and hyperparathyroidism.
Topics: Aniline Compounds; Calcium; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing | 2004 |
Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Topics: Aniline Compounds; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Phenethylamines; Propylamines; Vitamin D | 2005 |
[Calcimimetics--a new treatment for hyperparathyroidism?].
Topics: Allosteric Site; Aniline Compounds; Animals; Calcium; Calcium-Binding Proteins; Cinacalcet; Humans; Hyperparathyroidism; Naphthalenes; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Treatment Outcome | 2005 |
[Calcimimetics, mechanisms of action and therapeutic applications].
Topics: Aniline Compounds; Animals; Bone Remodeling; Calcium; Cells, Cultured; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Hyperplasia; Male; Middle Aged; Multicenter Studies as Topic; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroid Neoplasms; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic; Rats; Receptors, Calcium-Sensing; Renal Dialysis; Risk Factors; Time Factors; Uremia | 2005 |
[Calcium receptor/calcium-sensing receptor].
Topics: Aniline Compounds; Binding Sites; Calcium; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Mutation; Naphthalenes; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Signal Transduction | 2006 |
[Physiopathology and therapy of primary hyperparathyroidism].
Topics: Aniline Compounds; Humans; Hypercalcemia; Hyperparathyroidism; Parathyroidectomy; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 1999 |
The calcium receptor and calcimimetics.
Topics: Aniline Compounds; Animals; Bone Diseases; Calcium; Calcium-Binding Proteins; Drug Design; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Phenethylamines; Propylamines | 1999 |
Calcium-sensing receptor and calcimimetic agents.
Topics: Aniline Compounds; Animals; Calcium; Humans; Hyperparathyroidism; Kidney; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing; Receptors, Cell Surface | 1999 |
[Bone changes in primary hyperparathyroidism].
Topics: Aniline Compounds; Diagnosis, Differential; Diphosphonates; Estrogen Replacement Therapy; Humans; Hyperparathyroidism; Parathyroidectomy; Phenethylamines; Prognosis; Propylamines | 2002 |
1 trial(s) available for nps-568 and Hyperparathyroidism
| Article | Year |
|---|---|
Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism.
Topics: Aged; Aniline Compounds; Calcium; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperparathyroidism; Middle Aged; Parathyroid Hormone; Phenethylamines; Propylamines | 1997 |
8 other study(ies) available for nps-568 and Hyperparathyroidism
| Article | Year |
|---|---|
R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD).
Topics: Aniline Compounds; Animals; Calcinosis; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Hyperparathyroidism; Male; Minerals; Phenethylamines; Polycystic Kidney, Autosomal Dominant; Propylamines; Rats; Rats, Sprague-Dawley | 2009 |
Calcimimetic inhibits late-stage cyst growth in ADPKD.
Topics: Aniline Compounds; Animals; Calcium; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Fibrosis; Hyperparathyroidism; Kidney; Male; Parathyroid Hormone; Phenethylamines; Polycystic Kidney Diseases; Propylamines; Rats; Rats, Inbred Strains; Receptors, Calcium-Sensing; Severity of Illness Index | 2009 |
Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor.
Topics: Algorithms; Allosteric Regulation; Aniline Compounds; Animals; Calcium; Cell Line; Cricetinae; Cricetulus; Humans; Hypercalcemia; Hyperparathyroidism; Inositol Phosphates; Models, Biological; Mutation; Phenethylamines; Plasmids; Propylamines; Receptors, Calcium-Sensing; Transfection | 2009 |
Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.
Topics: Allosteric Site; Aniline Compounds; Calcimimetic Agents; Calcium; Cell Membrane; Cinacalcet; HEK293 Cells; Humans; Hyperparathyroidism; Kidney Diseases; Kidney Failure, Chronic; Ligands; Naphthalenes; Phenethylamines; Phosphorylation; Propylamines; Receptors, Calcium-Sensing; Signal Transduction; Treatment Outcome | 2012 |
Calcimimetic NPS R-568 induces hypotensive effect in spontaneously hypertensive rats.
Topics: Aniline Compounds; Animals; Blood Pressure; Calcium; Hyperparathyroidism; Hypertension; Hypotension; Male; Parathyroid Glands; Parathyroidectomy; Phenethylamines; Phosphates; Propylamines; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2005 |
The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands.
Topics: Aniline Compounds; Animals; Calcitriol; Calcium; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hyperparathyroidism; Hyperplasia; In Vitro Techniques; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Propylamines; Rats; Rats, Wistar; Receptors, Calcitriol; RNA, Messenger | 2007 |
A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.
Topics: Adult; Aged; Aniline Compounds; Calcitonin; Calcium; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phenethylamines; Propylamines | 1998 |
NPS R-568 halts or reverses osteitis fibrosa in uremic rats.
Topics: Aniline Compounds; Animals; Biomechanical Phenomena; Bone Density; Calcium; Creatinine; Femur; Fibrosis; Hyperparathyroidism; Kidney Function Tests; Male; Osteitis; Parathyroid Hormone; Phenethylamines; Propylamines; Radiography; Rats; Rats, Sprague-Dawley; Tibia; Uremia | 1998 |